Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM826SW)

Drug Name
PF-04236921 Drug Info
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 2 [1]
Systemic lupus erythematosus 4A40.0 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM826SW

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin (IL) TTF6I40 NOUNIPROTAC Inhibitor [3]
Interleukin-6 (IL6) TTT1V78 IL6_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-6 (IL6) DTT IL6 5.133 5.921 4.797 7.627
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Crohn disease
ICD Disease Classification DD70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-6 (IL6) DTT IL6 8.08E-01 -0.77 -1.15
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01405196) Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus. U.S. National Institutes of Health.
3 US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.